Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Vilon
Also known as: Lys-Glu, KE
Vilon is a synthetic dipeptide (Lys-Glu) developed as a thymus bioregulator in the Khavinson peptide research program. As the smallest peptide in the bioregulator series, its ability to exert meaningful biological effects is debated. In vitro and animal studies suggest immune-stimulating properties, but human evidence is minimal and of low quality.
Risk Level
Low RiskDifficulty
Beginner| Molecular Formula | C11H21N3O5 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Proposed to regulate gene expression in thymic and immune cells through direct DNA interaction. In vitro studies show increased lymphocyte proliferation and enhanced immune cell activity. Theorized to restore age-related thymic involution by reactivating gene expression in thymic epithelial cells.
Dosing Research
Oral capsules: 10 mg 1-2 times daily for 10-30 days. Being a dipeptide, oral bioavailability is questionable as it would be rapidly degraded by peptidases. Sublingual and intranasal routes have been suggested as alternatives.
Side Effects & Risks
No adverse effects reported in available literature. The extremely small size (dipeptide) means rapid degradation, limiting both therapeutic potential and toxicity risk. Long-term safety is uncharacterized.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.